About Bio-Rad Laboratories
Bio-Rad Laboratories has been a cornerstone of the life science research and clinical diagnostics industries since its founding in 1952, growing from a small chemistry supplier in Berkeley, California into a global manufacturer operating in more than 35 countries.
Life Science Research Tools
Bio-Rad is widely recognised as a leading supplier of instruments, reagents, and software for life science research. Its portfolio spans genomics, proteomics, gene expression, and cell biology, with particular strength in electrophoresis systems, western blotting platforms, PCR and digital PCR instruments, and flow cytometry. The company's ddPCR (droplet digital PCR) technology is an industry benchmark for the precise quantification of nucleic acids, widely adopted in oncology research, infectious disease monitoring, and gene therapy development.
Clinical Diagnostics Division
Alongside its research business, Bio-Rad operates a substantial clinical diagnostics division that produces quality controls, immunoassays, diabetes monitoring products, and autoimmune testing systems used by hospital and reference laboratories worldwide. Its quality assurance products, particularly haemoglobin A1c and immunology controls, are trusted reference standards in clinical laboratory accreditation programmes across multiple regulatory jurisdictions.
Headquartered in Hercules, California, Bio-Rad is publicly listed on the New York Stock Exchange under the ticker BIO and BIO.B, and the company has maintained its founding family involvement in governance throughout its history. Manufacturing and distribution infrastructure spans North America, Europe, and Asia-Pacific, supporting customers that include academic research institutions, pharmaceutical and biotechnology companies, government laboratories, and hospital diagnostics departments.
Bio-Rad's dual focus on enabling scientific discovery and supporting clinical accuracy gives it a distinctive position across both the upstream drug development pipeline and the downstream patient-care continuum. Continued investment in digital PCR, proteomics workflows, and automated diagnostics platforms reflects the company's long-standing commitment to precision measurement in biology and medicine.
Further information is available at bio-rad.com.
